Prostate cancer treatment guidelines: Why NICE must update active surveillance now

Imagine being told you have prostate cancer and then learning that the treatment you are offered could leave you with life-changing side effects, even though you might not need it at all. That is the reality facing thousands of men in the UK every year. Prostate Cancer UK now warns that up to 5,000 men annually are being put through unnecessary surgery or radiotherapy simply because the National Institute for Health and Care Excellence (NICE) has not updated its guidelines on active surveillance since 2021.The evidence for change is compelling. The groundbreaking ProtecT trial, published in the New England Journal of Medicine, tracked men with localised prostate cancer for 15 years and proved that active monitoring delivers the same survival outcomes as surgery or radiotherapy. The difference is that men who avoided radical treatment also avoided many of the harsh side effects, from incontinence to erectile dysfunction.This raises an urgent question: if the science is clear, why are so many men still being overtreated?The ProtecT trial remains one of the most influential studies in prostate cancer research. Following more than 1,600 men over 15 years, the trial compared three approaches: surgery, radiotherapy, and active monitoring. Researchers found no significant difference in survival between these groups.What did differ, however, was the quality of life. Men who underwent surgery or radiotherapy were far more likely to suffer from serious side effects such as urinary incontinence, bowel problems, and erectile dysfunction. Meanwhile, those placed under careful active surveillance maintained their quality of life without compromising their long-term survival.These results suggest that for many men with low-risk prostate cancer, aggressive treatment is not always necessary. Instead, regular check-ups, scans, and tests can safely monitor the condition until and unless it progresses.Despite the strength of this evidence, NICE guidelines on active surveillance have not been updated since 2021. Hospitals across England are left in a difficult position. Some strictly follow the older guidance, which leans more heavily toward immediate treatment. Others design their own protocols, creating inconsistency across the healthcare system.This lack of clarity means that thousands of men are pushed into invasive treatment when they could have safely been monitored. As a result, they experience avoidable side effects that impact daily life, relationships, and mental health.Updating the guidelines is not only about following the latest science. It is about ensuring that patients are given the most balanced, evidence-based options for their condition.Overtreatment in prostate cancer is not just a clinical issue. It has real human costs. For many men, the side effects of surgery or radiotherapy can last a lifetime. Erectile dysfunction and urinary incontinence are among the most common outcomes, stripping men of confidence and independence.Financial and emotional costs also come into play. Recovery from invasive treatment can take months, affecting a man’s ability to work or care for his family. The burden extends to partners and loved ones, who often become caregivers. All of this happens even though evidence shows that active monitoring could have been just as effective for survival in many cases.Active surveillance does not mean doing nothing. Instead, it involves a structured plan of monitoring, which may include PSA blood tests, MRI scans, and biopsies at regular intervals. If the cancer shows signs of growing or spreading, treatment can then begin at the right time.This approach empowers patients with more control over their choices. Men can avoid unnecessary procedures, while still having the safety net of intervention if it becomes needed later. For many, this balance between peace of mind and quality of life is invaluable.The call for updated NICE guidelines is not about ignoring treatment. It is about giving men the right treatment at the right time, guided by the most current scientific evidence. By modernising its approach, NICE could prevent thousands of men from enduring unnecessary harm while saving the NHS valuable resources.Change would also bring consistency. No longer would hospitals need to make their own rules or interpret outdated guidance. Instead, patients across the country could expect the same high standard of care, regardless of where they live.Prostate cancer care has advanced thanks to research like the ProtecT trial, but policy has not kept up. Outdated NICE guidelines are leaving thousands of men vulnerable to overtreatment and life-changing side effects that may not be needed. The science is clear. Active surveillance works, and it protects both survival and quality of life.For men and their families, the stakes could not be higher. Updating the guidelines is more than a technical matter. It is about dignity, well-being, and the right to make informed choices based on the strongest evidence available.Also read| What happens to your senses as you near death: The science explained